ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
The results of two subanalyses of the PACMAN-AMI trial were presented on the final day (2 September) of the European…
Cardiovascular
-
-
ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy
On 31 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic…
-
ESC 2024: Study highlights potential for Novartis to differentiate in HF space
On 30 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic…
-
Flagship, Quotient and Pfizer link on cardiovascular and renal disease
Flagship Pioneering and Quotient Therapeutics have entered a strategic partnership with Pfizer to identify new therapeutic targets for cardiovascular and…
-
US judge denies initial attempt by Novartis to block generic Entresto launch
Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering…
-
Bayer set to expand Kerendia’s label in cardiology with Phase III win
Bayer is looking to expand the use of Kerendia (finerenone) beyond type 2 diabetes (T2D), as the therapy showed efficacy…
-
MHRA approves Novo Nordisk’s semaglutide to cut cardiovascular risk
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of Novo Nordisk’s semaglutide, marketed as…
-
Cardurion closes $260m in Series B to develop cardiovascular pipeline
US-based cardiology biotech Cardurion Pharmaceuticals has raised $260m in Series B financing to advance its drug pipeline. The proceeds will…
-
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
-
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
Tectonic Therapeutic has completed a reverse merger with Avrobio and will begin trading on the Nasdaq global market as Tectonic…
